scholarly journals Liver and bone metastases from breast cancer: Eovist® magnetic resonance and diffusion weighted imaging, 18F-FDG positron emission/computed tomography

2016 ◽  
Vol 48 (2) ◽  
pp. 213
Author(s):  
Fabrizio Chegai ◽  
Serena Monti ◽  
Antonio Orlacchio ◽  
Lorenzo Mannelli
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Magnetic Resonance ◽  
Bone Metastases ◽  
Diffusion Weighted Imaging ◽  
Emission Computed Tomography ◽  
Positron Emission ◽  
Positron Emission Computed Tomography ◽  
18F Fdg ◽  
And Diffusion

scholarly journals F-18 fluorodeoxyglucose positron emission computed tomography in the diagnosis of pleural metastases from breast carcinoma

2020 ◽  
Vol 7 (3) ◽  
pp. 764
Author(s):  
Murat Saricam
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Pleural Effusion ◽  
Emission Computed Tomography ◽  
Pleural Effusions ◽  
Fdg Uptake ◽  
Positron Emission ◽  
Pet Ct ◽  
Positron Emission Computed Tomography ◽  
Pleural Metastases

Background: This study aimed to investigate the feasibility of F-18 fluorodeoxyglucose (FDG) positron emission computed tomography (PET/CT) in identifying the pleural invasion of metastatic breast cancers.Methods: A retrospective study was conducted to include 75 patients with untreated breast cancer who had undergone thoracoscopy to drain pleural effusions and to perform pleural biopsies. Whole group of patients were evaluated in terms of age, type of primary breast cancer, macroscopic appearance of pleura during thoracoscopy, maximum standardized FDG uptake value (SUV) reported by PET/CT scan in addition to presence of malignancy detected in pleura and/or pleural effusion.Results: All of 75 patients were female and mean age was 56.12±11.70. Metastatic disease was diagnosed in the pleura of 40 (53.3%) and in the pleural effusion of 43 (57.3%) patients. The sensitivity and specificity of PET/CT in detecting pleural metastases of breast carcinoma was calculated as 88.2% and 96.2% whereas PET/CT demonstrated sensitivity of 91.9% and specificity of 91.3% in identifying malignant pleural effusion. Cut-off values of FDG uptake were 4.25 for pleural metastases and 3.85 for malignant pleural effusions. PET/CT also indicated a false negative rate of 12.5%, a false positive rate of 16.28% and an overall accuracy rate of 85.33% in the diagnosis of pleural metastasis of breast carcinoma.Conclusions: PET/CT reporting an FDG uptake over 4 in the pleura or pleural effusion is beneficial in managing the patients with the suspicion of pleural metastases from breast cancer.

scholarly journals Case Report: Incidental Finding of COVID-19 Infection after Positron Emission Tomography/CT Imaging in a Patient with a Diagnosis of Histoplasmosis and Recurring Fever

2021 ◽  
Author(s):  
Camila Edith Stachera Stasiak ◽  
David Henrique Nigri ◽  
Fabrícius Rocha Cardoso ◽  
Raphael Santos de Almeida Rezende d Mattos ◽  
Philippe Alcântara Gonçalves Martins ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Case Report ◽  
Lower Lobe ◽  
Cervical Region ◽  
Emission Computed Tomography ◽  
Fdg Uptake ◽  
Emission Computed ◽  
Positron Emission ◽  
Positron Emission Computed Tomography ◽  
18F Fdg

This is a case report of a 37-year-old woman evaluated with 18F-fludeoxyglucose (18F-FDG) positron emission computed tomography/CT with recurrent fever after treatment with itraconazole for 6 weeks for histoplasmosis. The examination demonstrated a decrease in the dimensions of the pulmonary opacities previously identified in the left lower lobe and attributed to histoplasmosis. In addition to these pulmonary opacities, increased FDG uptake was also observed in lymph nodes present in the cervical region, mediastinum, left lung hilum, and hepatic hilum. Notably, other pulmonary opacities with ground-glass pattern that were not present in the previous computed tomography were detected in the right lower lobe, with mild 18F-FDG uptake. Nasal swab performed shortly after the examination was positive for COVID-19. In this case, the 18F-FDG positron emission computed tomography/CT study demonstrated findings consistent with active COVID-19 infection coexisting with inflammatory changes associated with histoplasmosis infection.

scholarly journals ANALYSIS OF THE DIAGNOSTIC VALUE OF MAGNETIC RESONANCE COMPUTER TOMOGRAPHY AND POSITRON EMISSION COMPUTER TOMOGRAPHY WITH 18F-FDG IN IDENTIFICATION OF SPINAL AND PELVIC BONE METASTASES

2021 ◽  
Vol 20 (5) ◽  
pp. 100-107
Author(s):  
A. V. Laryukov ◽  
R. Sh. Hasanov ◽  
Z. A. Afanasyeva ◽  
E. K. Laryukova
Keyword(s):  
Magnetic Resonance ◽  
Bone Metastases ◽  
Diagnostic Value ◽  
Diagnostic Techniques ◽  
Pelvic Bone ◽  
Emission Computed Tomography ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Pet Ct ◽  
Positron Emission Computed Tomography

Background. The treatment outcomes for non-small cell lung cancer (NSCLC) depend on the tumor stage and treatment strategy. The imaging techniques play a significant role in the diagnosis, staging and choice of appropriate treatment for NSCLC.Purpose of the study: сomparison of the diagnostic capabilities of magnetic resonance imaging (MR) and positron emission computed tomography to select the optimal approaches to early detection of spinal and pelvic bone metastases.Material and Methods. The treatment outcomes were analyzed in 71 patients with NSCLC. Spinal and pelvic bone metastases were detected in 24 patients using magnetic resonance imaging (MRI) and positron emission computed tomography (PET/CT). Multiple bone lesions were the most common. A total of 69 metastatic lesions were identified. To compare the capabilities of diagnostic techniques, all patients underwent PET/CT with 18F-FDG, and MRI of the spine and pelvic bones using diffused-weighted images (DWI). Statistical data processing included the calculation of the sensitivity, specificity and diagnostic accuracy of the above techniques.Conclusion. The comparative analysis of the capabilities of modern high-tech diagnostic techniques (PET/CT with 18F-FDG and MRI of the spine and pelvic bones with DWI) in early detection of bone metastases in patients with NSCLC, PET/CT with 18F-FDG showed the greatest diagnostic value. However, taking into account the high sensitivity and specificity of MRI with DVI in detection of bone metastases and limited availability of PET/CT for patients, MRI with DVI is recommended to exclude bone metastases. 

Bone Imaging in Metastatic Breast Cancer

2004 ◽  
Vol 22 (14) ◽  
pp. 2942-2953 ◽  
Author(s):  
Tsuyoshi Hamaoka ◽  
John E. Madewell ◽  
Donald A. Podoloff ◽  
Gabriel N. Hortobagyi ◽  
Naoto T. Ueno
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Bone Metastases ◽  
Single Photon ◽  
Photon Emission ◽  
Metastatic Breast ◽  
Response To Treatment ◽  
Emission Computed Tomography ◽  
Positron Emission ◽  
New Treatments

Bone is the most common site to which breast cancer metastasizes. Imaging—by skeletal scintigraphy, plain radiography, computed tomography, or magnetic resonance imaging—is an essential part, and positron emission tomography or single-photon emission computed tomography have a potential of evaluating bone metastases, but no consensus exists as to the best modality for diagnosing the lesion and for assessing its response to treatment. Imaging bone metastases is problematic because the lesions can be osteolytic, osteoblastic, or mixed, and imaging modalities are based on either direct anatomic visualization of the bone or tumor or indirect measurements of bone or tumor metabolism. Although bone metastases can be treated, their response to treatment is considered “unmeasurable” according to existing response criteria. Therefore, the process by which oncologists and radiologists diagnose and monitor the response of bone metastases needs revision, and the current inability to assess the response of bone metastases excludes patients with breast cancer and bone disease from participating in clinical trials of new treatments for breast cancer. In this review of the MEDLINE literature, we discuss the pros and cons of each modality for diagnosing bone metastases and for assessing their response to treatment and we present a practical approach for diagnosis and assessment of bone metastasis.

Sign in / Sign up

Export Citation Format

Share Document